Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  MacroGenics, Inc.    MGNX

MACROGENICS, INC.

(MGNX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/30/2020 12/01/2020 12/02/2020 12/03/2020 12/04/2020 Date
23.07(c) 23.69(c) 22.29(c) 22.59(c) 24(c) Last
521 437 541 552 602 798 544 957 563 734 Volume
0.00% +2.69% -5.91% +1.35% +6.24% Change
More quotes
Financials (USD)
Sales 2020 72,9 M - -
Net income 2020 -172 M - -
Net cash position 2020 139 M - -
P/E ratio 2020 -7,54x
Yield 2020 -
Sales 2021 153 M - -
Net income 2021 -102 M - -
Net cash position 2021 127 M - -
P/E ratio 2021 -15,5x
Yield 2021 -
Capitalization 1 349 M 1 349 M -
EV / Sales 2020 16,6x
EV / Sales 2021 8,01x
Nbr of Employees 384
Free-Float 94,9%
More Financials
Company
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of... 
More about the company
Notations Surperformance© of MacroGenics, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about MACROGENICS, INC.
11/30MACROGENICS INC : Entry into a Material Definitive Agreement (form 8-K)
AQ
11/30MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch a..
GL
11/30MacroGenics Announces Achievement of $25 Million in Milestones Related to Ret..
GL
11/09MACROGENICS : to Participate in Upcoming Investor Conferences
AQ
11/09MacroGenics to Participate in Upcoming Investor Conferences
GL
11/04MACROGENICS : 3Q Earnings Snapshot
AQ
11/04MACROGENICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
11/04MACROGENICS INC : Results of Operations and Financial Condition (form 8-K)
AQ
11/04MACROGENICS : Provides Update on Corporate Progress and Third Quarter 2020 Finan..
AQ
11/04MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Fina..
GL
11/04MACROGENICS : Announces Flotetuzumab and Tebotelimab Presentations at the ASH An..
AQ
11/04MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH A..
GL
10/29MACROGENICS : Announces Date of Third Quarter 2020 Financial Results Conference ..
AQ
10/28MACROGENICS : Announces Date of Third Quarter 2020 Financial Results Conference ..
AQ
10/28MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference..
GL
More news
News in other languages on MACROGENICS, INC.
2019BB Biotech mit höherem Verlust im zweiten Quartal
More news
Chart MACROGENICS, INC.
Duration : Period :
MacroGenics, Inc. Technical Analysis Chart | MGNX | US5560991094 | MarketScreener
Technical analysis trends MACROGENICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 28,33 $
Last Close Price 24,00 $
Spread / Highest target 58,3%
Spread / Average Target 18,1%
Spread / Lowest Target -66,7%
EPS Revisions
Managers
NameTitle
Scott E. Koenig President, Chief Executive Officer & Director
Paulo F. Costa Chairman
James Karrels Chief Financial Officer, Secretary & Senior VP
Ezio Bonvini Chief Scientific Officer & Senior VP-Research
Stephen L. Eck Chief Medical Officer & SVP-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
MACROGENICS, INC.120.59%1 349
GILEAD SCIENCES, INC.-5.26%77 167
VERTEX PHARMACEUTICALS4.28%59 372
REGENERON PHARMACEUTICALS31.15%51 975
WUXI APPTEC CO., LTD.68.65%41 218
BIONTECH SE254.19%28 894